In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Affectis Pharmaceuticals AG

Latest From Affectis Pharmaceuticals AG

Venture Creation Story: The Early Days Of Moderna

From pioneering stem-cell work to trade secrets a la Coca-Cola, what it means when a company – in this case, the RNA therapeutics developer Moderna – comes through Flagship Ventures’ VentureLabs group.

BioPharmaceutical United States

EMBL Ventures Snags $55 Million In First Closing For New European VC Fund

Despite an ongoing European financial crisis, Germany's EMBL Ventures collects $55 million for its next venture fund to invest in European biotech.

BioPharmaceutical Europe

Deals Shaping the Medical Industry (07/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Merck-Serono licenses 'brain-penetrant' anti-P2X7 programme from Affectis

Merck Serono (Merck KGaA) has signed an exclusive licensing agreement with Affectis Pharmaceuticals of Germany for the development and commercialisation of oral compounds targeting P2X7 receptors. The deal does not include Affectis' lead P2X7 antagonist, AFC-5128, which is in advanced preclinical development, Affectis' CBO Luc St-Onge told Scrip.

Orthopedics Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals